pre-seed
Stage
1
Investors
About
Anomer Bio is a London-based biotech startup focused on advancing glycoscience by developing synthetic monosaccharides aimed at enhancing immune responses and addressing complex health challenges. The company utilizes a proprietary platform that integrates multi-omics data, Nobel Prize-winning research tools, and clinical trial insights to design synthetic sugar therapeutics targeting glycans directly, with applications in immune and fibrotic diseases.
Explore Anomer Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.